Tetraspanins is a large family of membrane proteins that are implicated in cell proliferation, differentiation and tumor invasion. Specifically, the tetraspanin CD81 has been involved in cell proliferation but the mechanism is unknown. Here, we show that CD81 clustering stimulates ERK/MAPKinase activity and tyrosine phosphorylation of the adapter protein Shc in Huh7 cancer cells. In addition, overexpression of CD81 in HepG2 cells, NIH3T3 cells, and murine fibroblasts GD25 lacking the b1 family of integrins induces cell proliferation and ERK/ MAPKinase activation. Linked with this event, we observed an increase in CD81-associated type II phosphatidylinositol 4-kinase activity. A mutant in the PTB domain of Shc failed to interact with phosphoinositides and localize to the plasma membrane thus blocking CD81-induced ERK/MAPKinase activation. Therefore, we conclude that CD81 stimulates synthesis of phosphoinositides with the recruitment of Shc to the plasma membrane via PTB domain, and this sequence of events induces activation of ERK/MAPKinase. These findings define a novel mechanism of ERK/MAPKinase activation and tumor cell proliferation.
Introduction
Tetraspanins is a large family of transmembrane 4 superfamily proteins ubiquitously expressed that have four putative membrane-spanning domains, short Nand C-terminal cytoplasmic domains, a small intracellular loop, and two extracellular loops (Berditchevski, 2001; Hemler, 2001) . Although several tetraspanin molecules have been identified and implicated in the regulation of cell differentiation, proliferation, motility and tumor cell invasion, the biochemical functions of this class of molecules are still largely undefined. Recent experimental evidence suggests that tetraspanins play an important role in cell migration (Berditchevski et al., 2001; Hemler, 2001; Mazzocca et al., 2002) . This is supported by the observation of an inhibitory effect on cell motility following incubation with antibodies directed against tetraspanins in several cancer cell models. Conversely, studies concerning the role of tetraspanins in the process of cell proliferation are still scarce and limited to a few cell types. Tetraspanin CD81 was identified originally as the target of an antiproliferative antibody (TAPA-1) that inhibited in vitro cellular proliferation (Oren et al., 1990) . CD81 is involved in a broad range of cellular functions as revealed by the binding of monoclonal antibodies. The antibodies evoke their effect by mimicking a natural ligand or by altering the interactions between CD81 and its associated proteins. Although the protein is widely expressed, its levels within a single tissue vary during development and in response to cellular activation (Schick and Levy, 1993; Levy et al., 1998) . CD81 is considered a putative receptor for hepatitis C virus and it is required for Plasmodium falciparum sporozoite entry into hepatocytes (Silvie et al., 2003) . Recently, in a mouse model of skin tumor it has been demonstrated that the constitutive upregulation of CD81 was associated with an increased growth rate and tumor progression (Owens and Watt, 2001) . Moreover, mice with a CD81 null mutation revealed a defective proliferation of B lymphocytes in response to antigenreceptor crosslinking (Miyazaki et al., 1997; Maecker et al., 1998) .
CD81 is a nonglycosylated protein, and therefore it differs from other known tetraspanins that are glycosylated in either one of the two extracellular domains. Conversely, previous studies have shown that tetraspanin CD81 is linked to saturated acyl chains (Levy et al., 1991) . An important feature of tetraspanin CD81 is its ability to associate with one another and with various other transmembrane receptors (e.g. integrins) into membrane microdomains resembling 'lipid rafts' (Claas et al., 2001) . These membrane microdomains represent versatile devices for compartmentalizing different signaling functions. In the nonactivated state they float freely, carrying a few passenger proteins, but, when activated, they coalesce to form larger platforms where proteins meet to perform functions in signaling, processing and transport (Simons and Toomre, 2000) .
In the present study, we intended to demonstrate that CD81 activation contributes to organize a signaling complex resulting in ERK/MAPKinase activation and leading to liver tumor cell proliferation.
Results and discussion
Immunohistochemistry with specific antibody revealed that CD81 was found in sinusoidal cells of normal liver. A distinct signal was also observed in a limited number of stromal cells of portal field and central veins. Hepatocytes displayed a weak staining along plasma membranes. Hepatocytes of hyperplastic adenomatous nodules displayed a clear CD81 intensified staining along plasma membranes with a reduced cytoplasmic staining compared to normal hepatocytes (Figure 1a) .
To address the function of CD81, we used hepatocarcinoma cell lines HepG2 and Huh7, which showed a different expression pattern of CD81. Huh7 cells Figure 1 CD81 expression in liver tissue and cells. (a) Expression of CD81 in human normal liver and hyperplastic adenomatous nodule. Hepatocytes of hyperplastic adenomatous nodules displayed a CD81 intensified staining along plasma membranes with a reduced cytoplasmic staining compared to normal hepatocytes. (b) HepG2 and Huh7 cells analysed by FACScan and confocal laser microscopy showed a different expression pattern of CD81. Huh7 cells expressed CD81 prevalently at plasma membrane, whereas CD81, in HepG2, was localized into the cytosol ERK/MAPKinase activation by CD81 V Carloni et al expressed CD81 prevalently at the plasma membrane, whereas in HepG2 CD81 was confined only into the cytosol in comparison to tetraspanins CD63 and CD151 (Figure 1b) . It has been demonstrated that tetraspanins associates with the b1 integrin family and a stable association was reported with a3b1 integrin (Berditchevski et al., 1996; Yauch et al., 1998) . Therefore, we coimmunoprecipitated Huh7-a3b1 integrin with tetraspanins using different cell lysis detergents, specifically 1% CHAPS or 1% Triton X-100 (data not shown). In these cells, only the association between a3b1 integrin and tetraspanin CD151 was identified (Figure 2a) . Conversely, antibodies against CD63 and CD81 did not coimmunoprecipitate a3b1 integrins (Figure 2a) . Collectively, the data suggested that in these cells CD81 was not found to interact with the a3b1 integrin. Accordingly, other reports have demonstrated that CD81 is not associated with b1 integrin family members in some epithelial cell lines such as HeLa and A431 (Serru et al., 1999) .
To investigate whether CD81 stimulation was associated with biological effects, we performed the crosslinking of CD81 with the anti-CD81 monoclonal antibody JS-81 (overlapping results were also obtained using monoclonal antibody 1.3.3.22) adsorbed into the culture dishes. Serum-starved Huh7 cells that were plated onto culture dishes coated with anti-CD81 antibody for 1 h adhered and spread similarly as cells plated on laminin 1 or anti-b1 integrin mAb-coated surfaces (Figure 2b , left panels). In addition, Huh7 cells pretreated with an adhesion blocking antibody against b1 integrin (AIIB2) did not show abolishment of spreading induced by CD81. As expected, anti-b1 integrin mAb blocked completely the adhesion of cells to laminin (Figure 2b , right panels). It has been reported that the stimulation of CD81 leads to an increase of protein tyrosine phosphorylation levels (Schick and Levy, 1993) . Accordingly, we evaluated whether the crosslinking of CD81 resulted in increased protein tyrosine phosphorylation in Huh7 cells. Protein extracts from Huh7 cells plated on extracellular matrix or anti-CD81 immobilized antibody were immunoprecipitated with an anti-CD81 antibody and immunoblotted with an antiphosphotyrosine (anti-pTyr) or anti-Shc polyclonal antibody. Immunoblotting with anti-pTyr and anti-Shc antibodies indicated that crosslinking of CD81, but not HLA-I molecules, resulted in tyrosine phosphorylation of p46 and p52 Shc isoforms and association of Shc with CD81 ( Figure 3a) . Since Shc could potentially link CD81 to mitogenic ERK/MAPKinase signaling pathway (Ravichandran, 2001) , we tested whether the crosslinking of CD81 activated ERK/ MAPKinase. Accordingly, adhesion of Huh7 cells to anti-CD81 mAb-coated dishes caused activation of ERK/MAPKinase that was measured as the ability of the protein to phosphorylate myelin basic protein and by an antiphospho-ERK antibody (Figure 3b, c) .
To further investigate the role of CD81 in promoting cell proliferation and exclude the possibility that b1 integrins could contribute to the signaling pathway activated by CD81, we used murine fibroblasts lacking the b1 integrin family (GD25) (Fassler et al., 1995; Wennerberg et al., 2000) . GD25, NIH3T3 cells and HepG2 cells were transiently transfected with human CD81 allele (Figure 4a, b) . FACScan analysis of transfected cells (HepG2) showed effectively that CD81 was expressed on the plasma membrane ( Figure 4c ). After 72 h of culturing in cell growth assay, the cells were trypsinized, harvested and counted. We observed a twofold increase of cell number compared to GD25 transfected with the empty vector. However, it is worth to underline that the cells were transfected in the presence of serum, and we cannot rule out the possibility that CD81 could act facilitating the effect of some
Cell lysate I, lysed in 1% CHAPS buffer, and proteins from the lysate were immunoprecipitated with control IgG, anti-a3 integrin (clone P1B5), anti-CD63 (clone 6H1), anti-CD81 (clone JS-81), and anti-CD151 (clone 5C11). Proteins were resolved on 8% PAGE under nonreducing conditions. In the right panel, Huh7 cell lysates were prepared by using 1% CHAPS. Immunoprecipitations were performed with antibodies to the indicated molecules. Immunoprecipitated proteins were separated by 8% PAGE under nonreducing conditions and transferred to PVDF membrane. Immunoblot was then performed with anti-b1 polyclonal antibody. (b) In the left panels, Huh7 cells were plated for 1 h on immobilized antibodies anti-CD81 (CD81), laminin 1 (Ln) or anti-b1 integrin. In right panels, Huh7 cells were incubated with anti-b1 integrin mAb (AIIB2) then plated for 1 h on immobilized antibodies anti-CD81 or laminin 1. Cells were examined by contrast-phase microscopy ERK/MAPKinase activation by CD81 V Carloni et al growth factor receptors. Indeed, Wang et al. (2002) have demonstrated that overexpression of CD9, a tetraspanin that binds to the heparin-binding domain of HB-EGF is critical for promoting ErbB1 activation by HB-EGF and cell proliferation. Since the adapter protein Shc has been demonstrated to play a crucial role in cell proliferation, we also verified that HepG2 cells transfected with CD81 in combination with Shc triple mutant or Shc Y239/317F exhibited an inhibition of cell proliferation after 72 h (Figure 4b ). To our knowledge, this is the first demonstration that CD81 functions in promoting cell proliferation. Owing to the fact that CD81 apparently does not contain peptide sequences able to interact with Shc, we assumed that CD81 could interact with Shc indirectly. Some authors have recently demonstrated the highly specific association of CD81 with type II phosphatidylinositol 4-kinase (PtdIns 4-kinase) (Yauch and Hemler, 2000) . Huh7 cells showed a PtdIns 4-kinase activity associated with CD81 ( Figure 5a ). This lipid kinase was stimulated by 0.3% Triton X-100 and was strongly inhibited by the antiPtdIns 4-kinase mAb 4C5G (data not shown) or by 200 mM adenosine thus confirming the identity of type II PtdIns 4-kinase. Notably, this PtdIns 4-kinase activity was not inhibited by 10 mM wortmannin, thus excluding PtdIns 4-kinase activities belonging to PtdIns 3-kinase family. We hypothesized that overexpression of CD81 at the plasma membrane would increase PtdIns 4-kinase activity and phosphoinositides synthesis (i.e. phosphatidylinositol 4-phosphate, PtdIns 4-P). Upon transfection of GD25 cells with human CD81 allele, we found an increased PtdIns 4-kinase activity ( Figure 5b ). As expected, this activity was abolished by adenosine and was maintained in the presence of wortmannin (Fruman et al., 1998) . In addition, in order to study CD81-associated PtdIns 4-kinase activity, we evaluated whether PtdIns 4-P levels in membrane fractions were modified. Therefore, we measured PtdIns 4-P levels in GD25 membrane fractions transfected with empty vector (pcDNA) or pCD81. As shown in Figure 5c , GD25 cells transfected with CD81 allele exhibited increased PtdIns 4-P levels compared to mock-transfected cells. Taken together, these results can be interpreted considering the important signaling function of phosphoinositides metabolism. In fact, it has been recognized that phosphoinositide compartimentalization are of crucial importance in the organization of signaling microdomains. A growing number of kinases and phosphatases that act upon inositides have been identified in recent years. This finding together with the recognition and characterization of several protein motif that interact with inositides has contributed to understand how inositides impact to cellular signaling. In light of this function the importance of PtdIns 4-P formation has to be underlined. It can be safely assumed that PtdIns 4-P serves as a regulatory molecule.
Shc is a critical component of mitogenic pathways and it is composed by a N-terminal PTB domain, a central region termed CH1, and a C-terminal SH2 domain (Ravichandran, 2001) . One of the unexpected characteristics of Shc-PTB domain is its striking structural similarity to pleckstrin homology domains (PH) (Zhou et al., 1995) . PH domains have been shown to bind to acidic phospholipids. Consistent with the structural homology, Shc-PTB domain was found to bind acidic phospholipids such as PtdIns 4-P in vitro and in vivo (Rameh et al., 1997; Ravichandran et al., 1997) . These findings suggested that recruitment of Shc to the membrane could be regulated by new synthesis of acidic phospholipids induced by CD81. To address this aspect, GD25 cells were transfected with CD81 allele alone or in combination with GST tagged wild-type Shc or a triple mutant (R112Q, K116A, K139A) of the PTB domain unable to interact with PtdIns 4-P (Tanaka et al., 1995; Ravichandran et al., 1997) . We also used a (N17Ras) as control. We found that GD25 cells overexpressing CD81 induced activation of ERK/ MAPKinase evaluated by using a phospho-ERK antibody ( Figure 6a ) and coexpression of triple mutant Shc with CD81 blocked activation of ERK/MAPKinase. We also assessed whether coexpression of CD81, Y239/317FShc, a mutant unable to combine with adapter protein Grb2, or N17Ras impaired activation of ERK/MAPKinase. Introducing Y239/ 317FShc and N17Ras prevented the activation of ERK/MAPKinase (Figure 6a) . Moreover, the overexpression of CD81 stimulated the activation of ERK/MAPKinase into HepG2 (Figure 6b ) and NIH 3T3 cells (Figure 6c ) extending above results even in other cell lines. Importantly, transfection with dominant-negative Shc mutants inhibited ERK/MAPKinase activation. These data suggest that Shc plays a crucial role in the activation of ERK/MAPKinase pathway by CD81.
Next, we determined the effects of CD81 on the localization of Shc to the plasma membrane. Comparison of membrane localization of wild-type Shc and triple mutant Shc are shown in Figure 6d and e. The data revealed that CD81 expression increased localization of Shc to the plasma membrane and that phospholipid-binding sites of Shc-PTB appeared to be necessary and sufficient for membrane localization. The PTB domain of Shc has structural similarity to PH domains and may be considered as a subclass of PH domains (Zhou et al., 1995; Lemmon and Ferguson, 2000) . The wild-type Shc PTB domain mediates plasma membrane localization induced by CD81. Conversely, Shc with triple mutation (R112Q, K116A and K139A) fails to localize to the membrane and this aspect is consistent with a defective ability of CD81 to activate ERK/MAPKinase.
The results indicated that tetraspanin CD81 promotes cell proliferation and activates ERK/MAPKinase. Activation of ERK/MAPKinase induced by CD81 is mediated by de novo synthesis of PtdIns-4 P and recruitment of Shc to the plasma membrane. Although phosphatidylinositol (PtdIns) represents only a small percentage of total cellular phospholipids, it plays a crucial role in signal transduction as the precursor of several second messenger molecules. Thus, numerous derivatives of PtdIns (e.g. PtdIns 4,5-P2) have been found to have signaling roles in cytoskeletal assembly, membrane fusion and cell growth (Martin, 1998; Raucher et al., 2000) . These processes are spatially restricted to specific membrane domains. Many of the phosphoinositides are in low abundance in cells but at high in local concentrations in membrane domains (Kurzchalia and Parton, 1999) . It is likely that CD81 overexpression may recruit PtdIns 4-kinases in specific membrane compartments where they become activated (Minogue et al., 2001; Wei Yong et al., 2002) . The recruitment of Shc by PtdIns-4 P to such sites could allow the assembly of signal transduction complexes (Melkonian et al., 1999; Zhang and Samelson, 2000) . This hypothesis is sustained by the fact that CD81 overexpression or antibody-induced CD81 clustering could contribute to organize plasma membrane (Claas et al., 2001) . The plasma membrane comprises a complex mosaic of microdomains, the best characterized of these are lipid rafts and caveolae, although the presence of other microdomains cannot be ruled out. The significance of this mosaic structure lies in the lateral segregation that it can impose on signaling proteins, these can be concentrated or excluded from specific microdomains to increase the specificity and efficiency of signaling.
Further studies will be necessary to define the biological function of this molecular complex in health and liver disease. Ultimately, an understanding of hyperplastic adenomatous nodules pathophysiology, through more detailed molecular studies, should lead to more efficient and available early detection, and perhaps chemoprevention approaches to hepatic malignancy.
In summary, our results provide evidence that CD81 stimulates synthesis of phosphoinositides and recruitment of Shc to the plasma membrane by its PTB domain, leading to the activation of ERK/MAPKinase. According to these findings, we propose a novel mechanism of ERK/MAPKinase activation and tumor cell proliferation.
Materials and methods

Cell lines, antibodies and constructs
The following cell lines were used: HepG2 cells derived from a human hepatoblastoma; Huh7 cells derived from a hepatocellular carcinoma. The cells were maintained in Dulbecco's modified Eagle's medium (DMEM, Sigma Chemical Co., St Louis, MO, USA) and supplemented with 10% fetal bovine serum, 5 mM sodium pyruvate, and 5 mM nonessential amino acids at 371C in a humidified incubator containing 5% CO 2 . GD25 and NIH-3T3 cells were grown in DMEM supplemented with 10% fetal bovine serum. The murine fibroblastic cell line GD25 provided by R Fassler lacks the b1 family of integrins due to a disrupted b1 gene. Monoclonal antibodies used were JS-81, anti-CD81 (BD Pharmingen), 1.3.3.22, anti-CD81 (Chemicon), 6H1 anti-CD63 and 5C11 anti-CD151 provided by F Berditchevski (CRC Institut for Cancer Studies, University of Birmingham, UK) The rat monoclonal antibody anti-b1 integrin AIIB2 was from CH Damsky. Monoclonal anti-HLA I (cloneW6/32) was purchased from Sigma. Rabbit polyclonal anti-CD81 and anti-Shc were from Santa Cruz Biotechnology.
The constructs used were: human CD81 cDNA provided by Piero Pileri (Chiron, Siena Italy) was cloned in pcDNA 3.1. GST-tagged full-length wild-type Shc (ShcWT), full-length Shc with Y239F and Y317F mutations (Y239/317FShc), fulllength Shc with triple mutations of PTB domain (R112Q, K116A, K139A) were performed by site-directed mutagenesis employing a two-step PCR procedure. DNA fragments were subcloned in pEBG vector.
Immunofluorescence and confocal microscopy
For immunofluorescence analysis, Huh7 cells were plated in DMEM supplemented with 1% FBS on glass coverslips for 24 h then cells were fixed for 5 min with 2% paraformaldehyde in PBS, pH 7.2. Coverslips were blocked for 1 h with 3% heatinactivated bovine serum albumin (BSA) in PBS. Cells were stained with primary mAbs to tetraspanin anti-CD63 (clone 
Lipid kinase assay
Huh7 and GD25, this latter transfected in transient with empty vector or human CD81 allele and lipofectamine (Invitrogen), were serum-starved overnight and lysed in buffer containing 1% CHAPS, 20 mM HEPES (pH 7.5), 200 mM NaCl, 5 mM MgCl 2 200 mM Na 3 VO 4 , 2 mM NaF, 10 mM Na 4 P 3 O 7 , 2 mM phenylmethylsulfonyl fluoride. After immunoprecipitation with monoclonal antibody anti-CD81, immunocomplexes were washed four times in lysis buffer then reaction was performed directly on protein A-sepharose beads. The reaction buffer was 20 mM HEPES (pH 7.5), 10 mM MgCl 2 , 50 mM ATP, 0.3% Triton X-100, 10 mCi [ 32 P]ATP and 200 mg/ml sonicated L-a phosphatidylinositol (Avanti polar lipids, Alabaster, AL, USA) as a substrate. For some experiments, 200 mM adenosine (Sigma) was added to inhibit type II PtdIns 4-kinase reaction or 10 mM wortmannin. Reactions were carried out for 10 min at room temperature and stopped with 2 M HCl prior to extract lipids with chloroform/methanol (1 : 1, v/v). Lipid products were resolved by thin layer chromatography (TLC). TLC plates were exposed to O-Xmat film or beta-emitting radioactivity incorporated into [ 32 P] PtdIns was quantified using a Beta counter Analyzer (Perkin-Elmer, Boston, MA, USA). Measurement of phosphoinositides. Subconfluent cells were incubated overnight in 250 mCi of [ 32 P]orthophosphate (Amersham) in phosphate-free DMEM supplemented with 0.2% dialysed FCS (10 cm dish). Lipid extraction from mock-and CD81-transfected cells was performed as described above. HPLC analysis was carried out and PtdIns4-P level was measured as counts per minute (c.p.m.) A tritiated PtdIns 4-P standard was employed to identify the retention time of PtdIns4-P.
Immunoprecipitation and immunoblotting
Cells were surface labeled with Na 125 I washed, and lysed with 1% CHAPS (Sigma) buffer consisting of 10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.5 mM CaCl 2, 0.5 mM MgCl 2 , 0.02% NaN 3 , 1 mM PMSF, 1 mg/ml leupeptin, 1 mg/ml pepstatin A and 10 KIU/ml aprotinin for 30 min on ice. Alternatively 1% Triton X-100 buffer (Calbiochem) containing 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.5 mM CaCl 2, 0.5 mM MgCl 2 , 0.02% NaN 3 , 1 mM PMSF, 1 mg/ml leupeptin, 1 mg/ml pepstatin A and 10 KIU/ml aprotinin was used in some experiments.
For separation of membrane fractions, transfected GD25 cells were trypsinized and pelleted by centrifugation for 5 min at 500 g. Pellets were homogenized in TNE buffer (25 mM Tris, pH 7.5, 150 mM NaCl, 5 mM EDTA, and protease inhibitor) at 41C using a Dounce homogenizer. Homogenates were centrifuged for 5 min at 500 g and 41C. The supernatant was centrifuged for 1 h at 100 000 g and 41C. The resulting pellet was resuspended in 0.5 ml TNE buffer containing 1% Triton X-100 and proteins extracted for 30 min on ice. Tetraspanin molecules, a3b1 integrin (clone P1B5), and human HLA class I molecule (clone W6/32) were immunoprecipitated by incubation of cell lysates with 2-5 mg of specific monoclonal antibody immunoglobulin-Sepharose G overnight at 41C under constant agitation. The b1 integrin was also immunoprecipitated using the rat monoclonal antibody AIIB2 as positive control. Immunoprecipitates were washed four times in 1% lysis buffer followed by one wash in 0.1% lysis buffer, eluted with SDS-PAGE loading buffer at 951C for 5 min and separated on 12% PAGE gels under nonreducing conditions. Proteins were then transferred to polyvinyl difluoride (PVDF) membrane (Millipore, Bedford, MA, USA) and the membranes were blocked in 5% nonfat dry milk in PBS containing 0.05% Tween 20 for 1 h at room temperature. The membranes were subsequently incubated with the specific anti-b1 integrin polyclonal antibody for 2 h at room temperature under continuous shaking. After washing protein bands were visualized using HRPconjugated secondary antibody and Enhanced Chemiluminescence reagent (ECL, Amersham Pharmacia Biotech Inc.).
Immunohistochemistry
Wedge liver biopsies were obtained from 13 patients (eight females, five males, mean age 467 years; age range 25-63) undergoing uncomplicated cholecystectomy, with normal liver morphology. Surgical biopsy specimens were obtained from liver of 15 patients with hyperplastic adenomatous nodules (nine females, six males), (mean age 4776 years, age range 18-61). Diagnosis was based on clinical, laboratory, ultrasound and histological findings. Tissue samples were snap frozen and stored in liquid nitrogen. All experiments were carried out after the conclusion of diagnostic procedures. Informed consent was obtained from all patients prior to the surgical or bioptic procedure. The study was undertaken after approval by the University Ethical Committee.
Tissue sections were collected onto glass slides, fixed in acetone-chloroform for 30 min and immediately used after a brief air drying. Staining for CD81 was performed by employing the mouse monoclonal antibody anti-CD81, JS-81, at 1 : 50 dilution. Primary antibodies diluted in PBS -0.01% BSA were applied onto sections and incubated for 30 min at room temperature.
After a rinse in Tris-buffered saline (TBS), sections were incubated for 30 min with monoclonal mouse anti-rabbit antibodies (1 : 10) (Dakopatts), rinsed again in TBS and incubated with affinity-purified rabbit anti-mouse immunoglobulin antibodies (Dakopatts) (1 : 10) for 30 min, rinsed again in TBS and incubated with the alkaline phosphate-antialkaline phosphatase (APAAP) complex (1 : 50) (Dakopatts) for 30 min. The alkaline phosphatase substrate was developed with new fuchsin as described. Negative controls were performed by omission of the primary antibody, or its substitution with mouse immunoglobulins.
Abbreviations
PtdIns, phosphatidylinositol; PtdIns 4-kinase, phosphatidylinositol 4-kinase; PH, pleckstrin homology; PTB, phosphotyrosine binding; GST, glutathione S-transferase; PAGE, polyacrylamide gel electrophoresis; PIP, phosphatidylinositol monophosphate; ERK, extracellular-regulated kinase.
